Influx Healthtech Ltd.: Q4FY26 Business Update

Date: 21 April 2026 | Scrip Code: INFLUX

Key Highlights

Operational Performance: Year‑on‑year growth across nutraceutical, cosmetic, and veterinary lines; higher utilization and improved margin mix.
Capacity Expansion:
- New Quick Snap, Liquid Gel Sachet, 3‑Track Blister, Auto Coater, and Auto Powder Filling machines commissioned.
- Pet Food Line (1,000 kg/hr) FAT‑completed; additional bar production line booked.
- All capex (~₹5 Cr) funded from internal accruals.
Product Innovation: Launch of liposomal range, MMTC, capsule‑in‑capsule, and pellet technologies – targeting premium, science‑backed nutraceuticals.
Strategic Diversification: 100% subsidiary OLAHY Wellness Pvt Ltd. created to develop functional beverages and healthy snacks, marking a forward‑integration into B2C.
Regulatory Milestone: Successful audit clearance for operations in Tanzania, enhancing export readiness.
Outlook FY27: Management frames FY27 as a "scale + innovation" year, focusing on:
- Commercialisation of newly commissioned lines.
- Higher wallet share from existing clients.
- Entry into complex premium categories.
- Selective B2C expansion via OLAHEY.

Capex Discipline: Entire expansion funded internally, preserving cash reserves and avoiding dilution.
Margin Upside: New high‑margin formats (liposomal, MMTC) and improved utilization are expected to lift overall gross margins.
Revenue Diversification: OLAHEY and export‑ready capabilities open new revenue streams beyond traditional CDMO contracts.

Growth Levers: Capacity upgrades, product differentiation, and B2C entry.
Risk Factors: Execution risk on new lines, market acceptance of B2C products, competitive pressure in nutraceutical CDMO space, and macro‑economic volatility affecting consumer spending.
Regulatory Advantage: Tanzania audit clearance positions the firm for broader international market penetration.

Positive Momentum: Strong operational results and disciplined expansion suggest a solid growth trajectory.
Upside Potential: High‑margin product formats and B2C diversification could enhance earnings per share.
Watchpoints: Track rollout timelines for new equipment, OLAHEY’s market performance, and any changes in export regulations.

Prepared by the analyst team. All information is based on the company’s Q4FY26 business update and is subject to further verification.